Synonymous: | (1S,3R,4S)-9-[4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl]Guanine |
CAS: | 142217-69-4 |
Molecular Formula: | C12H15N5O3 |
Molecular Weight: | 277.279 |
Appearance | white to beige powder |
Storage | -20°C |
Category | Treatment of hepatitis B virus infection drugs |
Entecavir is a new generation of guanine nucleoside analogues used in the treatment of hepatitis B virus infection. It is mainly used to treat adult chronic hepatitis B with active viral replication and continuous elevated serum aminotransferase, or liver histologically active disease. It is the fastest and strongest nucleoside analogues with the lowest mutation rate. The data indicate that different chronic hepatitis B patients, including nucleoside and cirrhosis, can control the disease quickly and safely through the entecavir tablet, and arrive at the real end point of treatment easily, that is, hepatitis B virus is undetectable. By adhering to the treatment, a considerable number of patients can reach the satisfactory end point of treatment, that is, seroconversion of e antigen, and some patients can even reach the ideal end point of treatment, that is, negative conversion of surface antigen.
This product is suitable for active virus replication, It is also suitable for the treatment of chronic adult hepatitis B with persistent elevation of serum alanine aminotransferase (ALT) or liver histology showing active lesions. It is also suitable for the treatment of nucleoside untreated children with chronic HBV infection compensated liver disease aged 2 to < 18 years. There is evidence of active virus replication and persistent elevation of serum ALT level or histological evidence of moderate to severe inflammation and / or fibrosis.
It is prohibited for those allergic to entecavir or any ingredient in the preparation.
Patients should take entecavir under the guidance of doctors, and inform doctors of any new symptoms and drug combinations. The patient should be informed that if the drug is stopped, sometimes the liver condition will worsen, so the treatment method should be changed under the guidance of the doctor. Entecavir treatment did not reduce the risk of HBV transmission through sexual contact or contaminated blood sources. Therefore, appropriate protective measures need to be taken.